Magnesium Chloride - Uses, Dose, Side effects, MOA, Brands

Magnesium Chloride is available as an injection and oral formulation for the treatment and prevention of magnesium deficiency. It is also used as an oral dietary supplement.

Magnesium chloride Uses:

  • It is used for the treatment and prevention of hypomagnesemia in patients who are deficient or are at risk of magnesium deficiency.
  • As a dietary magnesium supplement.

Magnesium Chloride Dose in Adults:

Note: Serum magnesium is a poor reflection of the body magnesium as most of the magnesium is intracellular. Furthermore, the serum levels may be transiently normal or high after a few hours of the dose. It is best to aim for consistently high normal serum levels in patients with normal kidney functions for efficient repletion.

Magnesium Chloride Dose in the prevention of Hypomagnesemia (parenteral nutrition supplementation):

  • IV (elemental magnesium):
    • 8 to 20 mEq/day

Magnesium Chloride Dose as Dietary supplement:

  • Oral (Mag 64, Mag-Delay, Slow-Mag):
    • 2 tablets once a day.

Magnesium Chloride Dose in Childrens:

Note: Dosing presented in mg and mEq, verify dosing units; 1,000 mg of magnesium chloride = 119.7 mg elemental magnesium = 9.85 mEq elemental magnesium = 4.93 mmol elemental magnesium; Since the majority of magnesium is intracellular, the serum magnesium is poor reflection of repletional status. The serum concentrations may be transiently normal after a dose is given for a few hours; therefore, aim for high normal serum levels in patients with normal renal functions for efficient repletion.

Magnesium Chloride Dose in the treatment of Hypomagnesemia:

  • Infants, Children, and Adolescents:

    • Dose expressed as elemental magnesium:

      • IV:
        • 2.5 to 5 mg/kg/dose every six hours for 2 to 3 doses;
        • The dosing is based on experience with magnesium sulfate salt which is preferred.
      • Oral:
        • 10 to 20 mg/kg/dose up to four times a day.

Note: Patients with severe deficiency or those who require higher doses for rapid correction may need intravenous magnesium as oral formulations may result in diarrhea.

Magnesium Chloride Dose as maintenance requirement of Parenteral nutrition:

Note: Dose expressed as elemental magnesium:

  • Infants and Children ≤50 kg:

    • 3 to 0.5 mEq/kg/day intravenously
  • Children >50 kg and Adolescents:

    • 10 to 30 mEq/day IV

Pregnancy Risk Factor C

  • Animal studies have not yet been done. It can cross the placental boundary. It can cross the placental barrier.

Use during lactation:

  • It can be found in breast milk. It is found in breast milk.
  • The concentrations in lactating and nonlactating females are identical.

Dose in Kidney Disease:

  • The manufacturer recommends against its use in patients with renal impairment.
  • It is contraindicated in patients with kidney disease.

Dose in Liver disease:

There are no dosage adjustments provided in the manufacturer’s labeling.


Side effects of Magnesium Chloride:

  • Gastrointestinal:

    • Diarrhea with excessive oral doses
    • Nauses
    • vomiting
    • abdominal pain
  • Other:

    • Weakness
    • lethargy
    • cardiac arrhythmias
    • hypotension

Contraindications to Magnesium chloride:

  • Hypersensitivity to any ingredient of the formulation
  • Renal impairment
  • Myocardial disease
  • Coma

Warnings and precautions

  • Neuromuscular disease

    • Patients suffering from neuromuscular diseases such as myasthenia gravis or other similar conditions should be cautious.
  • Renal impairment

    • Patients with kidney disease may be more susceptible to magnesium accumulation. These patients should be cautious when using magnesium.

Magnesium chloride: Drug Interaction

Note: Drug Interaction Categories:

  • Risk Factor C: Monitor When Using Combination
  • Risk Factor D: Consider Treatment Modification
  • Risk Factor X: Avoid Concomitant Use

Risk Factor C (Monitor therapy)

Calcium Channel Blockers May enhance the adverse/toxic effect of Magnesium Salts. Magnesium Salts may enhance the hypotensive effect of Calcium Channel Blockers.
Neuromuscular-Blocking Agents Magnesium Salts may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.

Risk Factor D (Consider therapy modification)

Alfacalcidol May increase the serum concentration of Magnesium Salts.
Alpha-Lipoic Acid Magnesium Salts may decrease the absorption of Alpha-Lipoic Acid. AlphaLipoic Acid may decrease the absorption of Magnesium Salts.
Bictegravir Polyvalent Cation Containing Products may decrease the serum concentration of Bictegravir. Management: Administer bictegravir under fasting conditions at least 2 hours before or 6 hours after polyvalent cation containing products. Coadministration of bictegravir with or 2 hours after most polyvalent cation products is not recommended.
Bisphosphonate Derivatives Polyvalent Cation Containing Products may decrease the serum concentration of Bisphosphonate Derivatives. Management: Avoid administration of oral medications containing polyvalent cations within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate. Exceptions: Pamidronate; Zoledronic Acid.
Calcitriol (Systemic) May increase the serum concentration of Magnesium Salts. Management: Consider using a non-magnesium-containing antacid or phosphate-binding product in patients also receiving calcitriol. If magnesium-containing products must be used with calcitriol, serum magnesium concentrations should be monitored closely.
Deferiprone Polyvalent Cation Containing Products may decrease the serum concentration of Deferiprone. Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.
Dolutegravir Magnesium Salts may decrease the serum concentration of Dolutegravir. Management: Administer dolutegravir at least 2 hours before or 6 hours after oral magnesium salts. Administer the dolutegravir/rilpivirine combination product at least 4 hours before or 6 hours after oral magnesium salts.
Doxercalciferol May enhance the hypermagnesemic effect of Magnesium Salts. Management: Consider using a non-magnesium-containing antacid or phosphate-binding product in patients also receiving doxercalciferol. If magnesium-containing products must be used with doxercalciferol, serum magnesium concentrations should be monitored closely.
Eltrombopag Polyvalent Cation Containing Products may decrease the serum concentration of Eltrombopag. Management: Administer eltrombopag at least 2 hours before or 4 hours after oral administration of any polyvalent cation containing product.
Gabapentin Magnesium Salts may enhance the CNS depressant effect of Gabapentin. Specifically, high dose intravenous/epidural magnesium sulfate may enhance the CNS depressant effects of gabapentin. Magnesium Salts may decrease the serum concentration of Gabapentin. Management: Administer gabapentin at least 2 hours after use of a magnesiumcontaining antacid. Monitor patients closely for evidence of reduced response to gabapentin therapy. Monitor for CNS depression if high dose IV/epidural magnesium sulfate is used.
Levothyroxine Magnesium Salts may decrease the serum concentration of Levothyroxine. Management: Separate administration of oral levothyroxine and oral magnesium salts by at least 4 hours.
Multivitamins/Fluoride (with ADE) Magnesium Salts may decrease the serum concentration of Multivitamins/Fluoride (with ADE). Specifically, magnesium salts may decrease fluoride absorption. Management: To avoid this potential interaction separate the administration of magnesium salts from administration of a fluoride-containing product by at least 1 hour.
Mycophenolate Magnesium Salts may decrease the serum concentration of Mycophenolate. Management: Separate doses of mycophenolate and oral magnesium salts. Monitor for reduced effects of mycophenolate if taken concomitant with oral magnesium salts.
PenicillAMINE Polyvalent Cation Containing Products may decrease the serum concentration of PenicillAMINE. Management: Separate the administration of penicillamine and oral polyvalent cation containing products by at least 1 hour.
Phosphate Supplements Magnesium Salts may decrease the serum concentration of Phosphate Supplements. Management: Administer oral phosphate supplements as far apart from the administration of an oral magnesium salt as possible to minimize the significance of this interaction. Exceptions: Sodium Glycerophosphate Pentahydrate.
Quinolones Magnesium Salts may decrease the serum concentration of Quinolones. Management: Administer oral quinolones several hours before (4 h for moxi/pe/spar-, 2 h for others) or after (8 h for moxi-, 6 h for cipro/dela-, 4 h for lome/pe-, 3 h for gemi-, and 2 h for levo-, nor-, or ofloxacin or nalidixic acid) oral magnesium salts. Exceptions: LevoFLOXacin (Oral Inhalation).
Tetracyclines Magnesium Salts may decrease the absorption of Tetracyclines. Only applicable to oral preparations of each agent. Exceptions: Eravacycline.
Trientine Polyvalent Cation Containing Products may decrease the serum concentration of Trientine. Management: Avoid concomitant administration of trientine and oral products that contain polyvalent cations. If oral iron supplements are required, separate the administration by 2 hours. If other oral polyvalent cations are needed, separate administration by 1 hour.

Risk Factor X (Avoid combination)

Baloxavir Marboxil Polyvalent Cation Containing Products may decrease the serum concentration of Baloxavir Marboxil.
Raltegravir Magnesium Salts may decrease the serum concentration of Raltegravir. Management: Avoid the use of oral / enteral magnesium salts with raltegravir. No dose separation schedule has been established that adequately reduces the magnitude of interaction.

 

Monitoring parameters:

IV:

  • Monitor ECG, vital signs, and deep tendon reflexes especially when rapid administration is required;
  • Monitor magnesium, calcium, and potassium levels;
  • Monitor kidney function during administration

Oral:

  • Monitor kidney function;
  • Magnesium levels;
  • Bowel movements

How to administer Magnesium Chloride?

Oral formulations:

  • It should be administered after meals, at least two hours apart from other medications.

IV formulations:

  • It should be administered slowly as an intravenous infusion over a minimum period of 30 minutes.

Mechanism of action of Magnesium chloride:

  • Magnesium is a cofactor of many enzymes. 
  • Magnesium is required for proper functioning of around 300 enzymes.
  • It is a cofactor of enzymes involved in carbohydrate, protein, and lipid synthesis. 
  • It reduces serum cholesterol and acts on lipoprotein lipases. 
  • It can also act on the sodium/potassium ATPase, resulting in the polarization and reorganization of neurons.

Absorption:

  • Orally administered drugs are absorbed in inverse proportion to their amount.
  • Under controlled dietary conditions, 40% to 60% can be absorbed
  • Higher doses of the drug can result in a 15% to 36% absorption.

Distribution:

  • Half to 60% of magnesium goes to bones, and 1% to 2% to extracellular fluid.

Protein binding:

  • 30% of the drug is bound to albumin.

Excretion:

  • It is excreted in urine (as magnesium)

International Brand Names of Magnesium chloride:

  • Chloromag
  • Mag-SR Plus Calcium
  • Magdelay
  • Nu-Mag
  • Slow Magnesium/Calcium
  • Slow-Mag

Magnesium chloride Brand Names in Pakistan:

Magnesium Chloride Injection 3.25 mg/10ml in Pakistan

Cardioplegia Lahore Chemical & Pharmaceutical Works (Pvt) Ltd

 

Magnesium Chloride Solution 0.153 g/L in Pakistan

Hypertonic Solution Siza International (Pvt) Ltd.
Peri Solution Otsuka Pakistan Ltd.
Peritoneal Dialysis Soln With Dextrose Elko Organization (Pvt) Ltd.
Solvein Iso Siza International (Pvt) Ltd.

 

Magnesium Chloride Solution 0.2033 g/1000ml in Pakistan

Stereofundin Iso Usmanco International

Comments

NO Comments Found